Diabetes Drug Development Pipeline Report 2025

DelveInsight's comprehensive "Diabetes Pipeline Insight 2025" analysis delivers in-depth information on over 200 organizations and more than 200 investigational medications within the Diabetes development landscape. The report encompasses drug candidate profiles across both clinical and preclinical phases, offering therapeutic evaluations organized by product category, developmental phase, administration method, and molecular classification. Additionally, it spotlights dormant pipeline candidates in this therapeutic area.

Uncover emerging medications and therapeutic approaches in the Diabetes development pipeline through DelveInsight's extensive analysis @ Diabetes Pipeline Outlook

Major Highlights from the Diabetes Pipeline Analysis

As of December 04, 2025, Novo Nordisk A/S initiated a clinical investigation comparing two therapeutic agents for type 1 and type 2 diabetes management - faster aspart (an investigational formulation) and insulin aspart (a currently available prescription medication). Study participants will be randomly assigned to receive either faster aspart or insulin aspart (NovoRapid®). Both therapeutic agents will be administered alongside insulin degludec. Subjects will self-administer 4 daily injections: 3 doses administered 0-2 minutes prior to breakfast, lunch, and dinner, plus 1 dose at a consistent time daily. All investigational medications are supplied in pen delivery devices designed for subcutaneous insulin administration. The investigation duration spans approximately 7 months (30 weeks).

DelveInsight's Diabetes development pipeline analysis reveals a dynamic field with over 200 active organizations advancing more than 200 investigational therapies for Diabetes management.

Premier Diabetes pharmaceutical organizations include vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., among others.

Notable Diabetes investigational agents include Aspirin, DA-2811, Forxiga, TG103, and additional candidates.

Remain informed with the latest pipeline developments for Diabetes. Access information on clinical investigations, emerging therapeutic options, and leading pharmaceutical companies through DelveInsight @ Diabetes Treatment Drugs

The Diabetes Pipeline Analysis delivers disease background, pipeline landscape, and therapeutic evaluation of primary pipeline candidates within this therapeutic domain. The analysis also emphasizes unmet medical needs regarding Diabetes management.

Diabetes Disease Background

Diabetes represents a chronic metabolic condition marked by elevated blood glucose levels resulting from the body's compromised ability to manufacture or properly utilize insulin, a critical hormone for glucose regulation. The condition predominantly manifests in two principal forms: Type 1 diabetes, an autoimmune disorder where the immune system targets insulin-generating pancreatic cells, and Type 2 diabetes, which appears more frequently and typically correlates with insulin resistance alongside lifestyle elements including obesity and suboptimal nutrition. Additional variants encompass gestational diabetes, developing during pregnancy, and uncommon forms like Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).

Emerging Diabetes Drug Candidates Profile

Cadisegliatin: vTv Therapeutics

Cadisegliatin, alternatively designated as TTP399, represents an innovative oral therapeutic agent developed by vTv Therapeutics, engineered as a hepatic-selective glucokinase activator. Its purpose is to function as supplementary therapy to insulin for patients with type 1 diabetes (T1D). This medication has garnered recognition for its capability to enhance glycemic regulation by promoting hepatic glucose absorption and glycogen accumulation independent of insulin action, targeting a crucial requirement in diabetes care. Presently, this candidate is undergoing Phase III clinical investigation for Diabetes treatment.

LY-3209590: Eli Lilly and Company

Insulin efsitora alfa (LY3209590) constitutes a once-weekly basal insulin formulation, a fusion construct combining a novel single-chain insulin variant with a human IgG2 Fc domain. It is engineered specifically for weekly subcutaneous delivery, and through its minimal peak-to-trough fluctuation, demonstrates potential for delivering more consistent glucose concentrations (reduced glucose variability) across the week. Efsitora is currently in phase III development for adult patients with type 1 and type 2 diabetes.

CT-388: Roche

CT-388 is a once-weekly subcutaneous administration, dual GLP-1/GIP receptor agonist under development for obesity and type 2 diabetes (T2D) treatment. CT-388 was engineered to exhibit robust activity on both GLP-1 and GIP receptors while demonstrating minimal to absent ß-arrestin recruitment on either receptor. This biased signaling substantially reduces receptor internalization and subsequent desensitization, anticipated to yield extended pharmacological effectiveness. Currently, this agent is in Phase II clinical investigation for Type 2 Diabetes Mellitus treatment.

HU6: Rivus Pharmaceuticals

HU6 is an investigational, first-in-class oral therapeutic agent developed by Rivus Pharmaceuticals. It represents a novel drug category termed Controlled Metabolic Accelerators (CMAs), engineered to selectively enhance fat metabolism, producing fat reduction while maintaining muscle tissue. HU6 operates by modestly elevating resting metabolism, specifically through activating mitochondrial uncoupling. This mechanism increases oxidation of carbohydrates and lipids without diminishing ATP (energy) generation, yielding selective reduction of accumulated adipose tissue throughout the body. Currently, this candidate is in Phase II development for Diabetes treatment.

XW014: Sciwind Biosciences

XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for obesity and Diabetes (T2D) management. XW014 operates as a GLP-1 receptor agonist, replicating the function of the GLP-1 hormone secreted following meals. This hormone serves a crucial function in glucose metabolism regulation by stimulating insulin production, suppressing glucagon secretion, and enhancing satiety. As an oral small molecule, XW014 presents benefits compared to conventional peptide-based GLP-1 therapeutics, including simplified administration and potential for combination regimens with other oral agents. Presently, this drug is in Phase I clinical investigation for Diabetes treatment.

K-833: Kallyope Inc.

K-833 is an investigational oral small-molecule developed by Kallyope Inc., engineered as a nutrient receptor agonist for obesity and type 2 diabetes management. K-833, frequently investigated in combination with Kallyope's alternative candidate K-757, targets G-protein coupled receptors (specifically GPR119), which participate in hormone release that suppresses appetite and modulates glucose. Currently, this agent is in Phase I clinical investigation for Diabetes treatment.

Discover innovative therapeutics and clinical investigations in the Diabetes Pipeline through DelveInsight's comprehensive analysis @ New Diabetes Drugs

The Diabetes Pipeline Analysis Delivers Insights into

The analysis provides comprehensive information about organizations developing therapeutic interventions for Diabetes management with aggregate therapies developed by individual companies for this indication.

It evaluates various therapeutic candidates organized into early-stage, mid-stage, and late-stage development for Diabetes Treatment.

Diabetes pharmaceutical organizations are engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) programs.

Diabetes investigational drugs categorized by developmental phase, administration route, target receptor, monotherapy or combination approach, various mechanisms of action, and molecular classification.

Comprehensive analysis of partnerships (company-company collaborations and company-academic partnerships), licensing agreements, and financial arrangements for future progression of the Diabetes marketplace.

Diabetes Pharmaceutical Organizations

vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., and additional organizations.

The Diabetes pipeline analysis delivers therapeutic evaluation of pipeline medications by Administration Route. Agents have been classified under various administration routes including:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Diabetes Products have been organized under various Molecular classifications including:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Discover the future of Diabetes Treatment through insights on emerging drugs, pipeline advancements, and leading organizations via DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers

Coverage of the Diabetes Pipeline Analysis

Coverage: Global

Diabetes Pharmaceutical Organizations: vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., and additional organizations.

Diabetes Therapeutic Candidates: Aspirin, DA-2811, Forxiga, TG103, and additional agents.

Diabetes Therapeutic Evaluation by Product Category: Mono, Combination, Mono/Combination

Diabetes Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access current information on Diabetes Therapeutics and clinical investigations through DelveInsight's comprehensive pipeline analysis @ Diabetes Companies, Key Products and Unmet Needs

Report Structure

1. Introduction

2. Executive Summary

3. Diabetes: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Diabetes– DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Cadisegliatin: vTv Therapeutics

9. Drug profiles in the detailed report…..

10. Mid-Stage Products (Phase II)

11. CPL207280: Celon Pharma

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. KN056: Suzhou Alphamab Co., Ltd.

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Diabetes Key Companies

21. Diabetes Key Products

22. Diabetes- Unmet Needs

23. Diabetes- Market Drivers and Barriers

24. Diabetes- Future Perspectives and Conclusion

25. Diabetes Analyst Views

26. Diabetes Key Companies

27. Appendix

About DelveInsight

DelveInsight is a prominent healthcare-focused market research and consulting organization that delivers clients with premium market intelligence and analysis to facilitate informed strategic decisions. With a team of seasoned industry specialists and comprehensive understanding of the life sciences and healthcare industries, we provide customized research solutions and insights to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to maintain a competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com